Risk and outcome of acute myeloid leukaemia among survivors of primary diffuse large B-cell lymphoma: a retrospective observational study based on SEER database.
Yu DuYing WangQinlu LiXiaona ChangHeng ZhangMin XiaoShugang XingPublished in: BMJ open (2022)
The risk of developing sAML after DLBCL is substantial. Patients aged 60-74 years and with advanced-stage are more prone to sAML. And, compared with their dnAML counterparts, patients with sAML have a worse prognosis.
Keyphrases
- diffuse large b cell lymphoma
- epstein barr virus
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- liver failure
- prognostic factors
- bone marrow
- dendritic cells
- emergency department
- acute myeloid leukemia
- drug induced
- patient reported outcomes
- respiratory failure
- intensive care unit
- immune response